The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates from the Beat AML Master Trial
In this video, Prapti Patel, MD, University of Texas Southwestern Medical Center, Dallas, TX, discusses the results obtained from the Phase II sub-study of the Beat AML Master Trial (NCT03013998), which aimed to investigate the efficacy of ivosidenib (IVO) plus azacitidine (AZA) in older patients with IDH1-mutated acute myeloid leukemia (AML). First, Dr Patel explains the process behind patient selection, and gives an overview of the methodology used in this trial, including sequencing of mutations and treatment regimens offered to patients. Following this, Dr Patel discusses some of the results from the study, including the high overall response rate of patients at 6 months. To conclude, Dr Patel mentions the promising results seen in other Phase II and Phase III trials, including the AGILE trial (NCT03173248), which may benefit the future of therapeutic options for patients with AML. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
Disclosures
BMS-Celgene, Agios: Membership on an entity’s Board of Directors or advisory committees; Peerview: Honoraria.
